Brief: Ascletis Announces Promising Phase I Results In Australia For ASC47, Muscle-Preserving Weight Loss Drug for Obesity
07/11/2024 13:28
Nov 7 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES PROMISING RESULTS FROM A PHASE I STUDY
IN
AUSTRALIA FOR FIRST-IN-CLASS MUSCLE-PRESERVING WEIGHT LOSS DRUG
CANDIDATE ASC47 FOR THE TREATMENT OF OBESITY
* ASCLETIS PHARMA INC - ASC47 SHOWS MUSCLE-PRESERVING WEIGHT
LOSS
IN PRE-CLINICAL STUDIES
Source text: ID:nPn5XBjnda
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026